Therefore, the findings of our study, which showed a significantly higher rate of treatment failure among IBD patients on ADA in comparison to INF, prove that IBD patients from different nationalities or ethnic groups respond differently to anti-TNF agents. Here, CBLIF is linked to inflammatory bowel disease.